Astrea Bioseparations was founded in 1987 as a spinout from a Cambridge University working group. The original name was Affinity Chromatography Limited with the name changing through the years.
Most recently the company was known as Prometic Bioseparations until transitioning to Astrea Bioseparations in 2019. In 2020, the company became a wholly owned Gamma Biosciences company focused on helping bring advanced therapies to market.
Today, Astrea Bioseparations is honoured to be selected as a supplier delivering scalable, reliable solutions, with resins used in more than 20 FDA or EMA approved manufacturing processes.
What’s in a name?
The Greek “star-maiden”, Astrea, was the goddess of justice, innocence, purity, and precision represented by the constellation Virgo.
Our name, Astrea Bioseparations, reflects our own focus on purity, precision, and humanity in all we do. We use the constellation Virgo both as an allusion to the Greek myth and for the striking resemblance to a molecular diagram.
A commitment to quality
At Astrea Bioseparations every detail matters as we work to create tailored solutions that streamline bioprocesses from research through commercial phases. We actively support customers with products and services that enable them to Discover, Develop, and Deliver next-generation therapies to the market to treat or even cure diseases.
Our product portfolio includes standard and custom adsorbents and columns, complemented by our support services, that help customers run successful affinity chromatography and bioseparations projects.